Semaglutide removed from shortage list
It happened sooner than we expected -- the FDA has announced Semaglutide shortage resolution, removing it from the shortage list.
As announced by Novo Nordisk and the FDA itself, the shortage designation on Semaglutide has been lifted:
Center for Drug Evaluation and Research
FDA confirmed with the drug’s manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand. Patients and prescribers may still see intermittent and limited localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies.
GLP1.Guide covered this likelihood recently and have been waiting for clarification/development – unfortunately development happened even sooner than we anticipated.
Similar to the current stalemate, the FDA is pledging not to take action against compounding pharmacies to ensure that people are able to receive the crucial medications that GLP1 Receptor Agonists are now known to be.
Want to read the FDA statement and analysis on what might happen to compounders and supply? The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
